Engaging Patients to Support Adherence
|
|
- Ella Joy Green
- 5 years ago
- Views:
Transcription
1 Available at CurrentPsychiatry.com/BipolarDepression A SUPPLEMENT TO This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder. FIRST IN A SERIES OF 3 NEWSLETTERS JANUARY 2017 Engaging Patients to Support Adherence This newsletter series was developed and brought to you by Sunovion Pharmaceuticals Inc. It did not undergo peer review by Current Psychiatry. Newsletter content was developed in collaboration with the faculty. Faculty Vivien K. Burt, MD, PhD Professor Emeritus of Psychiatry Department of Psychiatry and Biobehavioral Sciences David Geffen School of Medicine at University of California, Los Angeles Co-Director The Women s Life Center Department of Psychiatry and Biobehavioral Sciences Resnick Neuropsychiatric Hospital at UCLA Los Angeles, California Catherine R. Judd, MS, PA-C, CAQ-Psychiatry, DFAAPA Clinical Assistant Professor Department of Physician Assistant Studies University of Texas Southwestern Medical Center School of Health Professions Physician Assistant Mental Health and Behavioral Medicine Parkland Health and Hospital System Dallas, Texas Mauricio Tohen, MD, DrPH, MBA Professor and Chairman Department of Psychiatry The University of New Mexico Albuquerque, New Mexico DISCLOSURES Dr. Burt serves or has served as a consultant and speaker for various pharmaceutical companies, including Sunovion. Ms. Judd and Dr. Tohen serve or have served as consultants, speakers, and researchers for various pharmaceutical companies, including Sunovion. The clinical expert commentary reflects the view of an actual licensed clinician who has been engaged by Sunovion. The information contained herein is intended for general informational purposes only and is not a substitute for your professional medical advice and judgment. This supplement is sponsored by LATUDA, SUNOVION, and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd Sunovion Pharmaceuticals Inc. All rights reserved. 11/16 LAT Please see Brief Summary of full Prescribing Information, including Boxed Warning, on page S5. LATUDA is indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established. IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years. A multidisciplinary panel of Clinical Experts contributed to the development of this 3-part newsletter series. Each issue explores strategies for the management of patients with bipolar disorder and features expert commentary from the psychiatry, primary care, or nurse-practitioner/ physician-assistant perspective. The Issue of Nonadherence in Bipolar Disorder Nonadherence to psychiatric medication is one of the main clinical challenges in the treatment of individuals with bipolar disorder. A recent cross-sectional study of 303 outpatients with the illness found that 69.3% had suboptimal adherence. 1 In multivariate analyses, depressive polarity of the last episode, current acute episode, presence of subsyndromal symptoms, and substance use or dependence emerged as predictors of poor treatment adherence. 1 Notably, patients with bipolar disorder spend the majority of their Watch a video about the impact of lifestyle factors on adherence and outcomes. Visit Supplement to Current Psychiatry Vol 16, No 1 January 2017 S1
2 ENGAGING PATIENTS TO SUPPORT ADHERENCE Skill Open-ended questions Affirmations Reflective listening Summaries TABLE 1. MOTIVATIONAL INTERVIEWING SKILLS AND EXAMPLES 4 Example Question(s) or Statement(s) Tell me about not taking your medication. What is good about it? And what is the other side? What worries you about not taking your medication? I understand that you didn t want to come back to the hospital, but you did anyway. I admire you for coming back to get help, knowing that it wasn t easy for you. You have recently lost a job, and that seems to be very hard for you. Let me stop us here and summarize some of the things that we ve just talked about. So you ve told me that you don t want to continue taking your medication because you have gained weight in the past. But at the same time, it sounds like you have had trouble managing your symptoms without your medication, which has impacted your marriage, your work, and your overall health. Did I miss anything? How do you feel about all these things? Laakso LJ. Motivational interviewing: addressing ambivalence to improve medication adherence in patients with bipolar disorder. Issues Ment Health Nurs. 2012;33(1):8-14. Reprinted by permission of Taylor & Francis Ltd. symptomatic time 68% in 1 study experiencing depressive symptoms, and the lifetime rate of comorbid substance use disorder in this population is 48%, suggesting that several of the factors that predict poor adherence predominate the bipolar disorder clinical picture. 2,3 The consequences of nonadherence in this patient population include increased total medical expenditures and outpatient mental health care costs due to greater risk for symptom exacerbation and recurrence, as well as lower treatment effectiveness and poorer treatment outcomes. 4 Several studies have found that patients with poor adherence also experience worse functional outcomes. 1 The effect of poor adherence to psychiatric medication may extend beyond a patient s mental health. In a recent study, Levin and colleagues found that greater depression severity particularly the presence of vegetative symptoms and retardation was significantly correlated with poor adherence to nonpsychiatric medication (P=.011 and P=.005, respectively), based on the Tablets Routine Questionnaire. 5 This finding is noteworthy because it demonstrates that nonadherence to psychiatric medication may cascade into nonadherence to medication for the treatment of medical comorbidities that are prevalent in patients with bipolar disorder. 6 Barriers to adherence in patients with bipolar disorder include both intentional factors (eg, anosognosia, or limited insight or lack of awareness about having a psychiatric disorder, and dislike of or concerns about side effects) and unintentional factors (eg, forgetting to take medication, possibly due to executive functioning deficits and lack of routines). External factors, such as financial problems, high cost of medication, lack of health insurance coverage, and poor relationships with health care professionals, may contribute to nonadherence. 4,8 Internal factors, such as lack of symptoms during euthymia and, in some cases, pleasure from the high energy and increased self-esteem experienced during mania, can make it difficult for patients with bipolar disorder to adhere to treatment regimens. 4 Furthermore, taking medication can reinforce for patients and family members the stigma frequently associated with mental illness. 4 The reasons for nonadherence are multifactorial and may transcend the individual patient. It is important for health care professionals to appreciate their role in treatment adherence, starting with a strong therapeutic alliance with their patients. 8 Strategies to Motivate Treatment Adherence Several strategies that can be employed by the multidisciplinary care team may improve adherence in patients with bipolar disorder. One strategy motivational interviewing involves a deeply humanistic approach to actively hearing patients own motivations for change and helping them to resolve the ambivalence with which they approach treatment. 4,9 The principles of motivational interviewing are: Expressing empathy so that patients feel understood and accepted 4 Encouraging patients to recognize a personally meaningful discrepancy between their goals and their current state to motivate change 4 Exploring patient resistance to better understand the individual s point of view, personal struggles, and obstacles to adherence, and then using these perspectives as a resource for finding answers and solutions 4 Supporting patients confidence in their ability to change (self-efficacy) 4 Four interaction techniques, known by the mnemonic OARS, form the foundation of this patient-centered approach (Table 1). 4 Psychoeducation is another strategy that specifically addresses misconceptions regarding bipolar disorder; it can be provided in a group setting or to patients and their partners or families. 10 Other efficacious approaches include cognitive-behavioral therapy, in which a patient s pattern of thoughts and feelings about medication and illness is systematically challenged to produce healthier behaviors and beliefs. 10 Regardless of the strategy used to explore and address a patient s motivation, knowledge gaps, or cognitive patterns, the plan should be individualized in terms of its accessibility, affordability, and practicality to optimize its implementation. 8 Effective interventions also encompass family members, whenever possible, and encourage continual interaction between patients and health care professionals, with the goal of fostering an understanding of bipolar disorder and its treatment options by all involved in the care of individuals with the illness. 10 Listen to a Clinical Expert talk about the use of motivational interviewing in clinical practice. Visit S2 Please see Brief Summary of full Prescribing Information, including Boxed Warning, on page S5. January 2017 Vol 16, No 1 Supplement to Current Psychiatry
3 LATUDA: A Treatment Option for Bipolar Depression The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA has not been established for longer-term use (more than 6 weeks) or for the treatment of mania associated with bipolar disorder. 11 The results of a phase 3, randomized, multicenter, double-blind, placebo-controlled clinical trial that examined the efficacy and safety of LATUDA monotherapy for patients with bipolar I depression were published in the February 2014 issue of The American Journal of Psychiatry. 12 Adult patients (N=505) with major depressive episodes associated with bipolar I disorder, with or without rapid cycling and without psychotic features, were evaluated for eligibility. 12 All psychotropic medications were tapered off, and patients were randomly assigned to 1 of 3 treatment groups: flexibly dosed LATUDA mg/day (N=166), flexibly dosed LATUDA mg/day (N=169), or placebo (N=170). 12 LATUDA dosing adjustments were permitted for patients in both LATUDA groups to optimize efficacy and tolerability. 12 Study medication was taken once daily in the evening by mouth with a meal (eg, dinner) or within 30 minutes after eating. 12 Short-term Efficacy Figure 1 shows the improvement in depressive symptoms for the LATUDA and placebo groups from baseline to Week 6 as measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) score, which was the study s primary efficacy endpoint. 12 The MADRS is a 10-item, clinician-rated scale with scores ranging from 0 to 60. At Week 6, LATUDA mg/day and mg/day were associated with significantly greater improvement in MADRS score from baseline to the 6-week endpoint than placebo (-15.4 for both LATUDA treatment groups vs for the placebo group; P<.001 for each LATUDA group vs placebo). 12 The higher dosage range ( mg/day) did not provide additional efficacy, on average, compared with the lower dosage range (20-60 mg/day). 12 Short-term Safety Figure 2 shows the incidence of adverse reactions occurring in 2% of patients in either LATUDA group and at greater incidence than placebo during acute therapy (up to 6 weeks in patients with bipolar depression). 11 Treatment was discontinued prematurely due to adverse events by 20 of 331 patients (6.0%) who received LATUDA mg/day, and by 9 of 168 patients (5.4%) who received placebo. 11 In the short-term study of LATUDA as monotherapy, the mean change in body weight from baseline to Week 6 was +1.2 pounds for patients who received LATUDA mg/day, 0.0 pounds LS Mean Change From Baseline Baseline Baseline mean = for patients who received LATUDA mg/day, and -0.1 pound for patients who received placebo. 11 Increase of body weight of at least 7.0% was noted for 2.4% of patients who received LATUDA versus 0.7% of patients who received placebo. 11 Changes in fasting glucose and lipids for the LATUDA and placebo groups are shown in Table The median prolactin concentration increased by 1.7 ng/ml for the LATUDA mg group, 3.5 ng/ml for the LATUDA mg Patients (%) FIGURE 1. PRIMARY EFFICACY ENDPOINT: MADRS SCORE 12 Time (Weeks) LATUDA mg (n=161) * ** Effect size: LATUDA mg: 0.51 LATUDA mg: 0.51 * ** LATUDA mg (n=162) Placebo (n=162) group, and 0.3 ng/ml for the placebo group. For male patients, the median change from baseline to Week 6 was +1.2 ng/ml, +1.9 ng/ml, and +0.4 ng/ml for the low-dose LATUDA, high-dose LATUDA, and placebo groups, respectively; for female patients, the corresponding median changes from baseline were +1.8 ng/ml, +5.3 ng/ml, and 0.0 ng/ml, respectively. 11 Extrapyramidal symptoms (EPS) observed during the 6-week LATUDA monotherapy study included ** *** ** *** *P<.05; **P<.01; ***P<.001. Abbreviations: LS, least squares; MADRS, Montgomery-Åsberg Depression Rating Scale. MADRS scale range, FIGURE 2. ADVERSE REACTIONS IN 2% OF LATUDA-TREATED PATIENTS AND AT GREATER INCIDENCE THAN PLABEBO LATUDA mg (N=164) Nausea Akathisia Somnolence* Dry Mouth LATUDA mg (N=167) EPS Diarrhea Anxiety Nasopharyngitis Back Pain Vomiting Placebo (N=168) UTI Influenza *** *** <1 <1 <1 <1 Abbreviations: EPS, extrapyramidal symptoms; UTI, urinary tract infection. *Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence. EPS includes bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus. Please see Brief Summary of full Prescribing Information, including Boxed Warning, on page S5. Supplement to Current Psychiatry Vol 16, No 1 January 2017 S3
4 ENGAGING PATIENTS TO SUPPORT ADHERENCE akathisia (noted for 8%, 11%, and 2% of patients in the LATUDA mg, LATUDA mg, and placebo groups, respectively), dystonia (0%, 2%, and 0%), parkinsonism (5%, 8%, and 2%), and restlessness (0%, 3%, and <1%). 11 EPS, akathisia, and dyskinesia were also examined using the Simpson-Angus Scale (SAS), the Barnes Akathisia Scale (BAS), and the Abnormal Involuntary Movement Scale (AIMS), respectively. 11 On the SAS, a shift from normal at baseline to an abnormal score at Week 6 (or at last observation carried forward for patients who discontinued prematurely) was noted for 3.7% of patients who received LATUDA mg/day versus 1.9% of patients receiving placebo. On the BAS, worsening from baseline to endpoint was noted for 8.4% versus 5.6% of patients who received LATUDA or placebo, respectively, whereas on the AIMS, worsening from baseline was noted for 3.4% of patients who received LATUDA versus 1.2% of those receiving placebo. 11 TABLE 2. CHANGE IN LABORATORY PARAMETERS FROM BASELINE TO WEEK 6 IN PATIENTS RANDOMIZED TO TREATMENT WITH LATUDA MONOTHERAPY OR PLACEBO 11 Parameter LATUDA mg LATUDA mg Placebo Glucose (mean) 0.8 mg/dl (n=140) +1.8 mg/dl (n=143) +1.8 mg/dl (n=148) Total cholesterol (mean) +1.2 mg/dl (n=140) 4.6 mg/dl (n=144) 3.2 mg/dl (n=147) Triglycerides (mean) +5.6 mg/dl (n=140) +0.4 mg/dl (n=144) +6.0 mg/dl (n=147) References 1. Montes JM, Maurino J, de Dios C, Medina E. Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning. Patient Prefer Adherence. 2013;7: Judd LL, Akiskal HS, Schettler PJ, et al. The longterm natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6): Simon NM, Otto MW, Weiss RD, et al. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004;24(5): Laakso LJ. Motivational interviewing: addressing ambivalence to improve medication adherence in patients with bipolar disorder. Issues Ment Health Nurs. 2012;33(1): Levin JB, Krivenko A, Bukach A, Tatsuoka C, Cassidy KA, Sajatovic M. A reexamination of nonpsychiatric medication adherence in individuals with bipolar disorder and medical comorbidities [published online June 10, 2016]. J Nerv Ment Dis doi: /NMD Maina G, Bechon E, Rigardetto S, Salvi V. General medical conditions are associated with delay to treatment in patients with bipolar disorder. Psychosomatics. 2013;54(5): Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1): Levin JB, Krivenko A, Howland M, Schlachet R, Sajatovic M. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs. 2016;30(9): McKenzie K, Chang YP. The effect of nurse-led motivational interviewing on medication adherence in patients with bipolar disorder. Perspect Psychiatr Care. 2015;51(1): Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv. 2004;55(3): LATUDA [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebocontrolled study. Am J Psychiatry. 2014;171(2): AN EXPERT S PERSPECTIVE Commentary by Vivien K. Burt, MD, PhD Among the challenges frequently faced by patients with bipolar disorder is adherence to treatment plans. As noted in this newsletter, a number of factors predict poor adherence, including a recent history of depression, current depressive symptoms (both severe and subsyndromal), and illicit substance use. In particular, I have found that bipolar depression, which is often so pervasive that it is difficult for patients to get out of bed, to leave home, or to see any hope for emerging from its debilitating effects, makes adherence more difficult. My clinical experience underscores the effectiveness of emotionally connecting with patients and encouraging them to express their concerns about prescribed medications and other aspects of their treatment regimen. By resonating with patients concerns and expressing a sincere appreciation for their real-life stresses, a continuum of trust is established that fosters adherence to treatment plans made in a multidisciplinary team setting. Empathizing with patients who struggle with bipolar disorder opens up avenues to explore the thoughts that have triggered those feelings. Once these thoughts have been expressed and shared with a caring and involved team of health care professionals, substantive discussions can be held to address and effectively treat symptoms, side effects, and other issues that hinder treatment adherence. Involving significant others and encouraging patient feedback can also support these efforts. Ultimately, I have found that an ongoing patient-provider dialogue helps improve psychiatric and medical outcomes in patients with bipolar disorder. Vivien K. Burt, MD, PhD S4 Please see Brief Summary of full Prescribing Information, including Boxed Warning, on page S5. January 2017 Vol 16, No 1 Supplement to Current Psychiatry
5 Supplement to Current Psychiatry Vol 16, No 1 January 2017 S5
6 S6 January 2017 Vol 16, No 1 Supplement to Current Psychiatry
7 Supplement to Current Psychiatry Vol 16, No 1 January 2017 S7
8 S8 January 2017 Vol 16, No 1 Supplement to Current Psychiatry
9 Supplement to Current Psychiatry Vol 16, No 1 January 2017 S9
10 S10 January 2017 Vol 16, No 1 Supplement to Current Psychiatry
11 Supplement to Current Psychiatry Vol 16, No 1 January 2017 S11
12 S12 January 2017 Vol 16, No 1 Supplement to Current Psychiatry
Engaging Patients to Support Adherence
This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder. FIRST IN A SERIES OF 3 NEWSLETTERS Faculty A SUPPLEMENT
More informationManaging Multiple Comorbidities in Bipolar Disorder
Available at CurrentPsychiatry.com/BipolarDepression A SUPPLEMENT TO This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar
More informationResearch suggests that as many as 1 in 5 primary care patients
Available at jfponline.com This promotional, non-cme content is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder. SECOND IN A SERIES OF 3 NEWSLETTERS
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationPlease see Brief Summary of full Prescribing Information, including Boxed Warning, on page S17.
SUPPLEMENT TO Available at CLINICIANREVIEWS.COM A F R O N T L I N E M E D I C A L C O M M U N I C AT I O N S P U B L I C AT I O N April 2015 Dezra L. Kenney, PMHCNS-BC, CADAC Danielle L. Kamine, MS, ARNP,
More informationNavigating Diagnosis in Bipolar Depression
CLINICAL EXPERTS IN BIPOLAR DEPRESSION Navigating Diagnosis in Bipolar Depression PRESENTATION This promotional, non-cme content is intended only for US health care professionals involved in the treatment
More informationBipolar disorder often coexists with other psychiatric disorders,
This promotional, non-cme content is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder. SECOND IN A SERIES OF 3 NEWSLETTERS A SUPPLEMENT TO Diagnosis:
More informationBipolar disorder is a recurrent and lifelong illness, with episodes
Available at CurrentPsychiatry.com/BipolarDepression This promotional, non-cme newsletter is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder.
More informationBipolar disorder, a mood disorder characterized by fluctuations
Available at jfponline.com This promotional, non-cme content is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder. first in a Series of 3 Newsletters
More informationBipolar Depression Diagnosis: Confounding Factors
This promotional, non-cme content is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder. SECOND IN A SERIES OF 3 NEWSLETTERS A SUPPLEMENT TO Diagnosis:
More informationMajor depressive episodes associated with bipolar I disorder (bipolar
Available at CLINICIANREVIEWS.COM A FRONTLINE MEDICAL COMMUNICATIONS PUBLICATION This promotional, non-cme content is intended only for healthcare professionals involved in the treatment of adult patients
More informationMajor depressive episodes associated with bipolar I disorder
Available at CurrentPsychiatry.com This promotional, non-cme content is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder. FIRST IN A SERIES OF
More informationBipolar disorder is characterized by fluctuations between hypomania,
Available at CurrentPsychiatry.com This promotional, non-cme content is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder. first in a Series of
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationBipolar disorder is a recurrent and lifelong illness, with episodes
Available at CurrentPsychiatry.com/BipolarDepression This promotional, non-cme newsletter is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder.
More informationBipolar Depression: A Collaborative Approach to Care
This promotional, non-cme content is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder. THIRD IN A SERIES OF 3 NEWSLETTERS Faculty A SUPPLEMENT
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patricia Moriarty Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationHelping a friend or loved one manage bipolar depression.
each month for up to 12 prescriptions Helping a friend or loved one manage bipolar depression. Please see Important Safety Information, including Boxed Warnings, on pages 18-21, and #1 Prescribed Branded
More informationThe Bipolar Depression Bulletin A Collaborative Care Approach to Diagnosing Bipolar Depression
The Bipolar Depression Bulletin A Collaborative Care Approach to Diagnosing Bipolar Depression Please see Brief Summary of full Prescribing Information, including Boxed Warning, on page 16. INDICATIONS
More informationLurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action
Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify
More informationConcomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.5, 7.1).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,
More informationAdherence in A Schizophrenia:
Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case
More informationDisclosure. What s this all about? From wrestling to dancing with patients: Motivational Interviewing in 10 minutes
From wrestling to dancing with patients: Motivational Interviewing in 10 minutes Delwyn Catley, Ph.D. Professor Department of Psychology University of Missouri Kansas City Disclosure I have no relevant
More informationManaging Multiple Comorbidities in Bipolar Disorder
SECOND IN A SERIES OF 3 NEWSLETTERS A SUPPLEMENT TO This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder. Managing
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationConcomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.6, 7.1).
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,
More informationStudy Design Results from PREVAIL 1 and PREVAIL 2
April 24, 2012 Company name: Dainippon Sumitomo Pharma Co., Ltd Representative: Masayo Tada, President (Securities Code: 4506, 1st Section of TSE and OSE) Contact: Atsuko Higuchi, Director Corporate Communication
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationThe Bipolar Depression Bulletin
The Bipolar Depression Bulletin Insights in the Diagnosis and Treatment of Bipolar Depression Please see Important Safety Information,, on page 15 INDICATIONS AND USAGE LATUDA is indicated for treatment
More informationAre You Up to Date? Latest Guidance for Evidence-Based Treatment of Adults With Bipolar Depression
Available at CurrentPsychiatry.com/BipolarDepression This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar disorder.
More informationFDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION
FOR IMMEDIATE RELEASE FDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION First and Only Non-systemic and Non-invasive Treatment Cleared for Patients Who Have Not Benefited From Prior Antidepressant
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationAre You Up to Date? Latest Guidance for Evidence-Based Treatment for Bipolar Depression
Available at CurrentPsychiatry.com/BipolarDepression THIRD IN A SERIES OF 3 NEWSLETTERS MAY 2017 A SUPPLEMENT TO This newsletter series was developed and brought to you by Sunovion Pharmaceuticals Inc.
More informationUnderstanding Bipolar Disorder
A Resource for Consumers Understanding Bipolar disorder is a brain disorder that affects people s moods. People with bipolar disorder have moods and feelings that are more extreme than normal ups and downs.
More informationTreatment for Bipolar Disorder
A Resource for Consumers Treatment for Living with bipolar disorder can be a challenge. With the help of your treatment team, family, friends, and by sticking to a treatment plan, you may be able to better
More informationPSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE
PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE Introduction and General Principles April 2017 Adapted for New Mexico from with permission from the Texas Department
More informationA guide to LATUDA for schizophrenia in adolescents
Putting it together: A guide to LATUDA for schizophrenia in adolescents Actor portrayal Please see Important Safety Information, including Boxed Warnings, on pages 15 17 and enclosed Medication Guide.
More informationBecome A Supporting Organization
Become A Supporting Organization 2018 Otuska Pharmaceutical Development & Commercialization, Inc. May 2018 MRC2.CORP.X.02619 Contents 1.0 Table Of Contents 1.1-1.7 PsychU Overview 1.1-1.2 Overview 1.3
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationLemilvo Tablets (aripiprazole)
Lemilvo Tablets (aripiprazole) Healthcare Professional Frequently Asked Questions (FAQ) Brochure Bipolar I Disorder in Adolescents Lemilvo (aripiprazole) is indicated for the treatment up to 12 weeks of
More informationBy using this card, you acknowledge that you currently meet the following eligibility requirements:
175941133 LATUDA Copay Savings Program Terms and Conditions By using this card, you acknowledge that you currently meet the following eligibility requirements: You must be 18 years of age or older to accept
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationWhat recovery means: Independent living. Control of symptoms. Active remission of substance use. Competitive employment
What recovery means: Independent living Control of symptoms Active remission of substance use Competitive employment Socialization with peers who do not use Satisfaction with life Getting finances in order
More informationA Type 2 Diabetes Discussion for Payers
THE ROLE OF MOTIVATIONAL INTERVIEWING IN PATIENT ENGAGEMENT A Type 2 Diabetes Discussion for Payers INTRODUCTION For members struggling with a chronic illness such as type 2 diabetes, a treatment plan
More informationUIDE. Annual Meeting. To The. American Psychiatric Association. Program Book New Research Exhibits Guide
Transforming Mental Health Through Leadership, Discovery and Collaboration UIDE American Psychiatric Association To The!!! 2011 Annual Meeting Program Book New Research Exhibits Guide 164th ANNUAL MEETING
More informationIndividualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool
Copyright John Donoghue 2015 Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 QUESTIONS Why do outcomes in schizophrenia remain
More informationMaximum Dose 30. mg/day. mg/day. mg/day. mg/day. 30 mg /day. mg/day. 15 mg /day 10. mg/day. mg/day
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARIPIPRAZOLE ORAL SOLUTION safely and effectively. See full prescribing information for ARIPIPRAZOLE
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More informationBehavior Change Counseling to Improve Adherence to New Diabetes Technology
Behavior Change Counseling to Improve Adherence to New Diabetes Technology Reinventing Diabetes Care for the 21st Century Robert A. Gabbay, M.D., Ph.D. Executive Director, Penn State Institute for Diabetes
More informationARIPIPRAZOLE tablets, for oral use Initial U.S. Approval: 2002
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationThe Bipolar Depression Bulletin
The Bipolar Depression Bulletin Bipolar Depression in Pediatric Patients Sponsored by Sunovion Pharmaceuticals Inc. Please see Important Safety Information, including BOXED WARNING, on page 13 INDICATIONS
More informationPSYCHIATRIC NEWS. Obama Calls for Major Initiative To Advance Brain Research 21 INSIDE
www.psychnews.org newspaper of the american psychiatric association volume 48, number 9, May 3, 2013 PSYCHIATRIC NEWS The First and Last Word in Psychiatry ISSN 0033-2704 Dilip Jeste, M.D., APA president,
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWhat is Motivational Interviewing?
What is Motivational Interviewing? Motivational Interviewing (MI) is a guiding style of communication that provides patients with the opportunity to create change in behaviors by providing a nonjudgmental
More informationIdentify the benefits of using a Brief Negotiated Intervention (BNI) to screen for alcohol and drug disorders. Review a four step model of Screening,
Kate Speck, PhD Identify the benefits of using a Brief Negotiated Intervention (BNI) to screen for alcohol and drug disorders. Review a four step model of Screening, Brief Intervention and Referral to
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFile NDA SE5 046/047, NDA SE5 036/037, NDA SE5 020/021
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: 18 June 2007 FROM: TO: SUBJECT: Mitchell V.
More informationBIPOLAR DISORDER. BIPOLAR DISORDER is. a lifelong illness. It affects. millions of people each. year. With proper treatment,
BIPOLAR DISORDER is a lifelong illness. It affects millions of people each year. With proper treatment, people with bipolar disorder can live normal lives. Work with your doctor to find treatment that
More informationWhat is Motivational Interviewing?
What is Motivational Interviewing? Motivational Interviewing (MI) is a guiding style of communication that provides patients with the opportunity to create change in behaviors by providing a nonjudgmental
More informationFAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals
FAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals Aripiprazole Dr. Reddy's 5, 10, 15 and 30 mg film-coated tablets Aripiprazole is indicated for the treatment up to 12 weeks of moderate-to-severe
More informationPsychopharmacological treatment of first episode psychosis
Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationMotivational Interviewing in Healthcare. Presented by: Christy Dauner, OTR
Motivational Interviewing in Healthcare Presented by: Christy Dauner, OTR The Spirit of MI Create an atmosphere of acceptance, trust, compassion and respect Find something you like or respect about every
More informationRISPERIDONE Tablets, USP, for oral use. Initial U.S. Approval: 1993
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RISPERIDONE safely and effectively. See full prescribing information for RISPERIDONE. RISPERIDONE
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationLiving well today...32 Hope for tomorrow...32
managing diabetes managing managing managing managing managing managing diabetes Scientific research continually increases our knowledge of diabetes and the tools to treat it. This chapter describes what
More informationElements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what
More informationYou wrote ZYPREXA. Will your patient leave the pharmacy with something else? (cetirizine HCl) have been mistaken, one for the other, in the past.
ZYPREXA (olanzapine)? You wrote ZYPREXA. Will your patient leave the pharmacy with something else? With over 4,000 drugs on the market and more than 8 million prescriptions filled every day, medication
More informationIntegrated Care for Depression, Anxiety and PTSD. Introduction: Overview of Clinical Roles and Ideas
Integrated Care for Depression, Anxiety and PTSD University of Washington An Evidence-based d Approach for Behavioral Health Professionals (LCSWs, MFTs, and RNs) Alameda Health Consortium November 15-16,
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOLANZAPINE tablets USP, for oral use OLANZAPINE orally disintegrating tablets USP, for oral use Initial U.S. Approval: 1996
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLANZAPINE safely and effectively. See full prescribing information for OLANZAPINE. OLANZAPINE tablets
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationHow To Treat Resistant Bipolar Patients
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/how-to-treat-resistant-bipolar-patients/3560/
More informationBehavioral Health Treatment in a Primary Care Setting
Behavioral Health Treatment in a Primary Care Setting Andrew J. McLean, MD, MPH Medical Director, ND DHS Chair, Psychiatry and Behavioral Science, UNDSMHS ajmclean@nd.gov Objectives Understand the importance
More informationImprove Patient Adherence with Motivational Interviewing
Improve Patient Adherence with Motivational Interviewing Bruce A. Berger, PhD President, Berger Consulting, LLC and Professor Emeritus, Auburn University Harrison School of Pharmacy bbergerconsulting@gmail.com
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Schizophrenia Schizophrenia is a mental illness with a number of symptoms, including confused or unclear thinking and speech,
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationVOLUME B. Elements of Psychological Treatment
VOLUME B Elements of Psychological Treatment Module 2 Motivating clients for treatment and addressing resistance Approaches to change Principles of Motivational Interviewing How to use motivational skills
More information10/24/2016. An Asthma Telehealth Program to Improve Adherence to Inhaled Corticosteroid Therapy. Disclosures. Overview of Presentation
An Asthma Telehealth Program to Improve Adherence to Inhaled Corticosteroid Therapy 11 th Annual Nemacolin Asthma Conference October 29, 2016 Andrew G Weinstein MD President, Asthma Management Systems
More informationUNDERSTANDING BIPOLAR DISORDER Young Adult: Get the Facts
UNDERSTANDING BIPOLAR DISORDER Young Adult: Get the Facts What does it mean when a health care professional says bipolar disorder? At first, it was quite scary Hearing a health care professional say you
More informationStigma and Bipolar Disorder
A Resource for Consumers Stigma and Stigma can occur when people unfairly judge others. People living with bipolar disorder can feel stigma related to their condition. However, there may be ways to address
More informationMotivational Interviewing in Chronic Diseases. Janelle W. Coughlin, Ph.D. Megan Lavery, Psy.D.. April 21, 2017
Motivational Interviewing in Chronic Diseases Janelle W. Coughlin, Ph.D. Megan Lavery, Psy.D.. April 21, 2017 Motivational Interviewing in Chronic Diseases Presenter Names: Janelle W. Coughlin, Ph.D. &
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationChoosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care
Choosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care JASON BEAMAN D.O., M.S., FAPA ASSISTANT CLINICAL PROFESSOR CHAIR, DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES OKLAHOMA STATE
More informationEU Risk Management Plan
6.2 Elements for Public Summary - Abilify 6.2.1 Overview of Disease Epidemiology Bipolar I Disorder Reported prevalence rates for bipolar I disorder differ due to local variations in psychiatric practice,
More information